# Nuclide record idea-reg-alpha-emitter-portfolio (idea). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/ideas/idea-reg-alpha-emitter-portfolio/>
  a schema:CreativeWork ;
  nuclide:kind "idea" ;
  schema:identifier "idea-reg-alpha-emitter-portfolio" ;
  schema:name "Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211"@en ;
  schema:description "Almost every alpha cancer therapy in development relies on one scarce isotope. Developing several alternatives at once would stop the whole field waiting on a single supply chain."@en ;
  schema:url <https://nuclide.cc/ideas/idea-reg-alpha-emitter-portfolio/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2018.0977> ;
  nuclide:related <https://nuclide.cc/isotopes/ac-225/>, <https://nuclide.cc/isotopes/pb-212/>, <https://nuclide.cc/isotopes/at-211/>, <https://nuclide.cc/isotopes/ra-224/> ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:companies <https://nuclide.cc/companies/orano-med/>, <https://nuclide.cc/companies/perspective-therapeutics/> ;
  nuclide:terms <https://nuclide.cc/terms/alpha-vs-beta/> ;
  nuclide:bottlenecks <https://nuclide.cc/bottlenecks/b-manufacturing-cell-therapy/> .